NCT01951677 - Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

October 31, 2017

Study Completion Date

May 31, 2019

Conditions

Exposure to Hepatitis B Virus

Interventions

DRUG

HBsAg

Standard hepatitis B vaccine antigen

BIOLOGICAL

PreS HBsAg

preS hepatitis B surface antigen

BIOLOGICAL

Advax-1(TM)

Adjuvant formulated with vaccine antigen

BIOLOGICAL

Advax-2(TM)

Adjuvant formulated with vaccine antigen

BIOLOGICAL

Advax-3(TM)

Adjuvant formulated with vaccine antigen

BIOLOGICAL

Alum

Adjuvant formulated with vaccine antigen

Trial Locations (1)

Flinders Medical Centre, Adelaide